Milan, Lombardy, Italy Indaco Venture Partners is the famous VC, which was founded in 2016. The fund was located in Europe if to be more exact in Italy. The main office of represented VC is situated in the Milan.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Indaco Venture Partners, startups are often financed by The FSE Group, Octopus Ventures, Oxford Capital Partners. The meaningful sponsors for the fund in investment in the same round are Oxford Capital Partners, Octopus Ventures, Guillaume d'Eyssautier. In the next rounds fund is usually obtained by Oxford Capital Partners, Octopus Ventures, Guillaume d'Eyssautier.
The average startup value when the investment from Indaco Venture Partners is 5-10 millions dollars. The real fund results show that this VC is 23 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Indaco Venture Partners performs on 22 percentage points less the average number of lead investments. The top amount of exits for fund were in 2016. The important activity for fund was in 2019. The fund is constantly included in 2-6 deals per year. The usual things for fund are deals in the range of 5 - 10 millions dollars.
The overall number of key employees were 8.
We can highlight the next thriving fund investment areas, such as Medical Device, Biopharma. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - Italy. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Among the most popular portfolio startups of the fund, we may highlight Talent Garden, Bendit, CellPly.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Allied Irish Banks | Dublin, Ireland, Irishtown |
| Beijing Qingchuang Chengzhang Touzi | Beijing, Beijing, China |
| Cambrian Venture Capital | China, Huangpu, Shanghai |
| China Baoan Group | China, Guangdong Province, Luohu District |
| Doorway platform | - |
| Great Noble International | - |
| GREYSTAR | Charleston, South Carolina, United States |
| Haoyu Guquan | China, Shaanxi, Yanan |
| JASTEC | Japan, Tokyo |
| Javelin Capital | England, London, United Kingdom |
| Jinfu New Material | - |
| Kemexel Ventures (KEMEXEL GROUP COMPANIES) | - |
| King Capital Partners | Dallas, Texas, United States |
| KMD Venture | - |
| Lehman Brothers | New York, New York, United States |
| Panacea Capital Advisors | Bethesda, Maryland, United States |
| Techstars Korea Accelerator | Seoul, Seoul-t'ukpyolsi, South Korea |
| Think Food Group | District of Columbia, United States, Washington |
| Vertical Venture Partners | California, Menlo Park, United States |
| Winroader | Japan, Tokyo |
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Nouscom | $8M | 21 Mar 2024 | Basel, Basel-City, Switzerland | ||
Freya Biosciences | $38M | 12 Dec 2023 | Boston, Massachusetts, United States | ||
Hoba Therapeutics | $27M | 10 Dec 2023 | Copenhagen, Capital Region of Denmark, Denmark | ||
Nouscom | $79M | 14 Nov 2023 | Basel, Basel-City, Switzerland | ||
D-Orbit | $118M | 08 Nov 2023 | Milan, Lombardy, Italy | ||
Alia Therapeutics | $5M | 17 Apr 2023 | Trento, Trentino-Alto Adige, Italy | ||
Sibylla Biotech | $27M | 04 Oct 2022 | Trento, Trentino-Alto Adige, Italy | ||
InnovHeart | $55M | 27 Jan 2022 | Milan, Lombardy, Italy | ||
CYSEC | $4M | 20 Jan 2022 | Lausanne, Vaud, Switzerland |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Nouscom | $8M | 21 Mar 2024 | Basel, Basel-City, Switzerland | ||
Freya Biosciences | $38M | 12 Dec 2023 | Boston, Massachusetts, United States | ||
Hoba Therapeutics | $27M | 10 Dec 2023 | Copenhagen, Capital Region of Denmark, Denmark | ||
Nouscom | $79M | 14 Nov 2023 | Basel, Basel-City, Switzerland | ||
D-Orbit | $118M | 08 Nov 2023 | Milan, Lombardy, Italy | ||
Alia Therapeutics | $5M | 17 Apr 2023 | Trento, Trentino-Alto Adige, Italy | ||
Sibylla Biotech | $27M | 04 Oct 2022 | Trento, Trentino-Alto Adige, Italy | ||
InnovHeart | $55M | 27 Jan 2022 | Milan, Lombardy, Italy | ||
CYSEC | $4M | 20 Jan 2022 | Lausanne, Vaud, Switzerland |
